Abstract 330P
Background
After radiotherapy (RT) to the left breast, the long-term risk of developing various cardiovascular diseases may increase. In our study, we present how deep inspiration treatment changes the doses of organs at risk (OAR), especially the heart. Furthermore, we examined if there is a relationship between the size of the irradiated target area and the dose on the heart.
Methods
From May 2016 to August 2020, 503 patients with left-sided breast cancer underwent RT at our institute. Since May 2018, we have treated our patients in deep breathing (DIBH) using the “voluntary breath-hold” technique. We compared the Dmean and Dmax values for the most critical OAR (left lung, heart, left ventricle, LAD-left anterior descending artery) based on the two treatment methodologies. Subsequently, both groups were then further subdivided into whether the treatment was given by standard fractionation or hypofractionation and created 3-3 groups based on the size of the target area (PTV).
Results
In patients treated with normal fractionation in DIBH vs. without, the doses of the OARs were the following: lung Dmean: 9.3 Gy vs. 9.96 Gy (p=0.029), left ventricle Dmean: 3.52 Gy vs. 7.56 Gy (p=2.69E-27), heart Dmean: 2.78 vs. 5.31 (p=1.11E-24), LAD Dmean 12.17 vs. 25.91 Gy (p=4.63E-24) respectively. In the hypofractionated group with vs. without DIBH the values were lung Dmean: 7.43 Gy vs. 8.08 Gy (p=0.17), left ventricle Dmean: 3.48 Gy vs 6.4 Gy (p=2.64E-10), heart Dmean: 2.64 vs 4.62 (p=2.96E-08), LAD Dmean 11.46 vs 18.35 Gy (p=3.37E-06) respectively. In the standard fractionated group, the average doses for each structure decreased mostly in women with large breast sizes after DIBH treatment. Generally, as the breast size increases, the values of the left ventricle, heart, and LAD increase, whilst the values of the lungs decrease. Although, a significant difference could only be detected in a few categories.
Conclusions
DIBH RT of the left breast significantly reduces radiation exposure to crucial OAR than free-breathing radiation therapy. At the same time, the coverage of the target area does not change, and our results suggest that this benefit is most pronounced in patients with large breast sizes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
292P - Unlocking the potential of circulating miRNAs in predicting response to neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis
Presenter: Paola Tiberio
Session: Poster session 02
294P - Prognostic significance and evolution of HER2 zero, HER2 low and HER2 positive in breast cancer after neoadjuvant treatment
Presenter: Tong Wei
Session: Poster session 02
295P - ESR1, PGR, ERBB2, MKI67 single gene analysis in neoadjuvant-treated early breast cancer patients
Presenter: Rebekks Spiller
Session: Poster session 02
296P - Identification of metabolism-related therapeutic targets to improve response to neoadjuvant chemotherapy in early breast cancers
Presenter: Françoise Derouane
Session: Poster session 02
297P - Prognostic and predictive impact of NOTCH1 in early breast cancer
Presenter: Julia Engel
Session: Poster session 02
298P - Association of luminal-androgen receptor (LAR) subtype with low HER2 in triple-negative breast cancer
Presenter: Lee Min Ji
Session: Poster session 02
299P - Single-cell transcriptomic analysis reveals specific luminal and T cell subpopulations associated with response to neoadjuvant therapy in early-stage breast cancer
Presenter: Xiaoxiao Wang
Session: Poster session 02
300P - Correlation of PD-L1 protein and mRNA expression and their prognostic impact in triple-negative breast cancer
Presenter: Kathleen Schüler
Session: Poster session 02
301P - Epigenetic modifications of IL-17 gene in patients with early breast cancer and healthy controls
Presenter: Ljubica Radmilovic Varga
Session: Poster session 02
302P - Clinicopathological features and outcomes of pregnancy associated breast cancer: Case control study -single institution experience
Presenter: Nashwa Kordy
Session: Poster session 02